Unicycive Therapeutics Management
Management criteria checks 2/4
Unicycive Therapeutics' CEO is Shalabh Gupta, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is $4.07M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 5.75% of the company’s shares, worth $3.52M. The average tenure of the management team and the board of directors is 3.9 years and 4.3 years respectively.
Key information
Shalabh Gupta
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 13.5% |
| CEO tenure | 8.3yrs |
| CEO ownership | 5.8% |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 21
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$4m | US$550k | -US$31m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$30m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$2m | US$550k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$670k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$3m |
| Dec 31 2020 | US$644k | US$495k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | US$400k | US$350k | -US$2m |
| Dec 31 2018 | US$187k | US$146k | -US$1m |
Compensation vs Market: Shalabh's total compensation ($USD4.07M) is above average for companies of similar size in the US market ($USD646.00K).
Compensation vs Earnings: Shalabh's compensation has increased whilst the company is unprofitable.
CEO
Shalabh Gupta (51 yo)
8.3yrs
Tenure
US$4,071,562
Compensation
Dr. Shalabh K. Gupta, M.D., MPA., Founded Unicycive Therapeutics, Inc. and serves as its Chairman of the Board and also serves as its Chief Executive Officer, President and Director since August 2016. He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.3yrs | US$4.07m | 5.75% $ 3.5m | |
| Executive Vice President of Pharmaceutical & Business Operations | 4.2yrs | US$1.53m | 0.040% $ 24.7k | |
| Executive Vice President of Corporate Strategy | 3yrs | US$1.27m | 0.17% $ 103.3k | |
| Chief Financial Officer | 3.7yrs | US$383.12k | no data |
3.9yrs
Average Tenure
62yo
Average Age
Experienced Management: UNCY's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.3yrs | US$4.07m | 5.75% $ 3.5m | |
| Independent Director | 1.7yrs | US$138.58k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.2yrs | US$135.58k | no data | |
| Independent Director | 6.8yrs | US$181.02k | 0.10% $ 62.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.3yrs
Average Tenure
52yo
Average Age
Experienced Board: UNCY's board of directors are considered experienced (4.3 years average tenure).